Sign in
LENZ Stock Price, Chart, Stats & News
LENZ Therapeutics, Inc.
Save
LENZ chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.16% |
Operating margin | -477.46% |
Pretax margin | -427.62% |
Net margin | -430.25% |
Effective tax rate | -0.62% |
ROA | -26.85% |
ROE | -37.47% |
D/E | 0.00x |
Interest coverage ratio | – |
LENZ valuation
P/E | – |
P/S | 13.80x |
P/B | 0.92x |
P/CF | -3.77x |
P/FCF | -3.76x |
P/OCF | -3.77x |
PEG | 0.10x |
EV multiple | -3.25x |
About
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
Similar securities
Based on sector and market capitalization
Report issue